US$ 29.74
eli lilly glp-1 winner An Analyst Just Declared the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right? StockWatch: Investors Hammer Lilly as
Description
Even though they have been proven to reduce the risk of major adverse cardiovascular events, their effectiveness in treating heart failure is unknown

As global demand rises for effective metabolic therapies, GLP-1 drug development remains one of the fastest-growing segments in biopharma innovation

GLP1 drugs like Ozempic and Wegovy are transforming obesity and diabetes care

GLP-1= glucagon-like peptide-1
A balanced microbiome environment can help support pathways involved in energy metabolism and appetite regulation
Participants Patients with type 2 diabetes
